Brecanavir (INN; codenamed GW640385) is a protease inhibitor which has been studied for the treatment of HIV. In December 2006, its developer, GlaxoSmithKline...
4 KB (126 words) - 13:33, 19 December 2023
(INN) Bravecto Bravecto Plus Bravelle brazergoline (INN) Breathtek UBT Brecanavir (INN, INN) Breezee Mist Antifungal brefonalol (INN) bremazocine (INN)...
6 KB (333 words) - 02:39, 1 July 2024
finger protein transcription factor Failed agents Aplaviroc Atevirdine Brecanavir Capravirine Dexelvucitabine Droxinavir Lasinavir Emivirine Lersivirine...
15 KB (1,230 words) - 02:38, 16 July 2024
finger protein transcription factor Failed agents Aplaviroc Atevirdine Brecanavir Capravirine Dexelvucitabine Droxinavir Lasinavir Emivirine Lersivirine...
28 KB (2,975 words) - 02:18, 11 August 2024
2006, GlaxoSmithKline discontinued the phase II clinical development of brecanavir, an investigational protease inhibitor for the treatment of HIV, due to...
33 KB (4,117 words) - 22:23, 23 August 2022
2020 it was entered into clinical trials for the treatment of COVID-19. Brecanavir TMC-647055 Dierynck I, Van Marck H, Van Ginderen M, Jonckers TH, Nalam...
3 KB (228 words) - 09:53, 23 March 2024
finger protein transcription factor Failed agents Aplaviroc Atevirdine Brecanavir Capravirine Dexelvucitabine Droxinavir Lasinavir Emivirine Lersivirine...
3 KB (338 words) - 13:45, 27 July 2023